Tarsus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tarsus Pharmaceuticals (TARS).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$89Upside to Avg. PT+20.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$116
Sep 16, 2026	Barclays	Glen Santangelo	Reinstates	Overweight	$110
Sep 8, 2026	Jefferies	Anthony Petrone	PT Raise	Buy	$88→$105
Aug 12, 2026	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$97→$100
Jul 31, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$100→$98
Jul 21, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$90→$89
Jul 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$88
May 4, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$88
Feb 25, 2026	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$95→$105
Feb 25, 2026	Guggenheim	Eddie Hickman	PT Raise	Buy	$87→$90
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$100
Nov 20, 2025	Mizuho	Graig Suvannavejh	Initiate	Outperform	$100
Nov 5, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$84→$87
Oct 20, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$72→$88
May 27, 2025	HC Wainwright & Co.	Matthew Caufield	Assumes	Buy	$72
May 5, 2025	Goldman Sachs	Andrea Tan	PT Raise	Neutral	$46→$51
May 2, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$78→$84
Mar 6, 2025	Jefferies	Anthony Petrone	PT Raise	Buy	$54→$58
Feb 26, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$75→$78
Feb 26, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$73

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.

Benzinga Newsdesk

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.

Benzinga Newsdesk

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

People Also Watch

People Also Watch

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PROBarclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PROJefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PROOppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PROMizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PROGuggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

People Also Watch

People Also Watch

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89